Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB and 19 more

Show all authors

Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC

The New England journal of medicine25 Aug 2023Cited by 1,372 (Europe PMC)

PMID37622681DOI10.1056/nejmoa2306963PepBankPUB-37622681

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with heart failure with preserved ejection fraction and obesity, semaglutide improved the KCCQ clinical summary score more than placebo.
In plain wordsIn adults with obesity and heart failure, semaglutide improved symptom scores more than placebo.
Peptide
Semaglutide
Outcome
IncreaseKCCQ-CSS change
Study
n = 529
Comparator
Placebo
Analysis
Primary
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
KCCQ-CSS change
16.6 points
semaglutide
KCCQ-CSS change
8.7 points
placebo
estimated difference
7.8 points
semaglutide vs placebo
Source sentences
Summary
The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3762268101
02HumanRandomized controlled trialEfficacy outcome
In adults with heart failure with preserved ejection fraction and obesity, semaglutide reduced body weight more than placebo.
In plain wordsIn adults with obesity and heart failure, semaglutide led to more weight loss than placebo.
Peptide
Semaglutide
Outcome
DecreaseBody weight percentage change
Study
n = 529
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
body weight change
−13.3%
semaglutide
body weight change
−2.6%
placebo
estimated difference
−10.7 percentage points
semaglutide vs placebo
Source sentences
Summary
and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3762268102
03HumanRandomized controlled trialEfficacy outcome
In adults with heart failure with preserved ejection fraction and obesity, semaglutide increased 6-minute walk distance more than placebo.
In plain wordsIn adults with obesity and heart failure, semaglutide increased walking distance more than placebo.
Peptide
Semaglutide
Outcome
Increase6-minute walk distance change
Study
n = 529
Comparator
Placebo
Analysis
Secondary
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
6-minute walk distance change
21.5 m
semaglutide
6-minute walk distance change
1.2 m
placebo
estimated difference
20.3 m
semaglutide vs placebo
Source sentences
Summary
The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3762268103
04HumanRandomized controlled trialEfficacy outcome
In adults with heart failure with preserved ejection fraction and obesity, semaglutide produced more wins than placebo in the hierarchical composite end point.
In plain wordsIn adults with obesity and heart failure, a combined measure of outcomes favored semaglutide over placebo.
Peptide
Semaglutide
Outcome
IncreaseHierarchical composite end point
Study
n = 529
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
win ratio
1.72 ratio
semaglutide vs placebo
Source sentences
Summary
In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3762268104
05HumanRandomized controlled trialEfficacy outcome
In adults with heart failure with preserved ejection fraction and obesity, semaglutide lowered C-reactive protein more than placebo.
In plain wordsIn adults with obesity and heart failure, semaglutide lowered an inflammation marker more than placebo.
Peptide
Semaglutide
Outcome
DecreaseC-reactive protein percentage change
Study
n = 529
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
CRP change
−43.5%
semaglutide
CRP change
−7.3%
placebo
estimated treatment ratio
0.61 ratio
semaglutide vs placebo
Source sentences
Summary
The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3762268105
06HumanRandomized controlled trialSafety outcome
In adults with heart failure with preserved ejection fraction and obesity, fewer participants had serious adverse events with semaglutide than with placebo.
In plain wordsIn adults with obesity and heart failure, fewer people had serious adverse events with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
DecreaseSerious adverse events
Study
n = 529
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
2.4 mg once weekly · 52 weeksAs given in this study (human).
Measurements
participants with serious adverse events
35 participants
semaglutide
participants with serious adverse events
71 participants
placebo
Source sentences
Summary
Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks.
Report a problemFND-3762268106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 3NCT07738276

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

Shahid Beheshti University of Medical Sciencesn = 60est. 18 Jul 2026 to est. 22 Dec 2027

Heart Failure and Reduced Ejection Fraction · Obesity & Overweight · Tirzepatide

Trial page ClinicalTrials.govUpdated 3 Aug 2026

CompletedPhase 3Results postedNCT04788511

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

Novo Nordisk A/Sn = 52916 Mar 2021 to 18 Apr 2023

Obesity

Trial page ClinicalTrials.govUpdated 5 Dec 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.